NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage

Journal of Clinical Investigation

Volumn 125, Issue 4, 2015, Pages 1433-1445

  Xiong, Wenjun ^a   Garfinkel, Alexandra E MacColl ^a   Li, Yiqing ^b   Benowitz, Larry I ^b   Cepko, Constance L ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; GLUTATHIONE PEROXIDASE 1; MANGANESE SUPEROXIDE DISMUTASE; PARVOVIRUS VECTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; NFE2L2 PROTEIN, MOUSE; PPARGC1A PROTEIN, MOUSE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; GENE CONTROL; LIPID PEROXIDATION; MOUSE; NERVE DEGENERATION; NERVE INJURY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA GANGLION CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; APOPTOSIS; C57BL MOUSE; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; MUTANT MOUSE STRAIN; NERVE CELL; NERVE CRUSH; OPTIC NERVE INJURIES; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA CONE; RETINITIS PIGMENTOSA; THERAPEUTIC USE;

ANIMALS; APOPTOSIS; CATALASE; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NERVE CRUSH; NERVE DEGENERATION; NEURONS; NF-E2-RELATED FACTOR 2; OPTIC NERVE INJURIES; OXIDATIVE STRESS; RETINAL CONE PHOTORECEPTOR CELLS; RETINAL GANGLION CELLS; RETINITIS PIGMENTOSA; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTORS;

EID: 84981229351     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79735     Document Type: Article

References (98)

1. Guzman JN, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature. 2010;468(7324):696-700.
2. Nunomura A, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(8):759-767.
3. Ferrante RJ, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997;69(5):2064-2074.
4. Parkinson Study Group QE3 Investigators, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-552.
5. Lloret A, Badia MC, Mora NJ, Pallardo FV, Alonso MD, Vina J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis. 2009;17(1):143-149.
6. Petersen RC, et al. Vitamin E and Donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
7. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of diability in early parkinson's disease. N Engl J Med. 1993;328(3):176-183.
8. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 2001;40(8):959-975.
9. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003;15(2):247-254.
10. St-Pierre J, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127(2):397-408.
11. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem. 2003;278(14):12029-12038.
12. Wu Z, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999;98(1):115-124.
13. Itoh K, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236(2):313-322.
14. Itoh K, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13(1):76-86.
15. Howden R. Nrf2 and cardiovascular defense. Oxid Med Cell Longev. 2013;2013:104308.
16. Joshi G, Johnson JA. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov. 2012;7(3):218-229.
17. Tan SM, de Haan JB. Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much? Redox Rep. 2014;19(3):107-117.
18. Mazzuferi M, Kumar G, van Eyll J, Danis B, Foerch P, Kaminski RM. Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy. Ann Neurol. 2013;74(4):560-568.
19. Pomeshchik Y, et al. Does Nrf2 gene transfer facilitate recovery after contusion spinal cord injury? Antioxid Redox Signal. 2014;20(8):1313-1323.
20. Wang CY, et al. CD36 upregulation mediated by intranasal LV-NRF2 treatment mitigates hypoxia-induced progression of Alzheimer'slike pathogenesis. Antioxid Redox Signal. 2014;21(16):2208-2230.
21. Chen B, Tang L. Protective effects of catalase on retinal ischemia/reperfusion injury in rats. Exp Eye Res. 2011;93(5):599-606.
22. Rex TS, et al. Adenovirus-mediated delivery of catalase to retinal pigment epithelial cells protects neighboring photoreceptors from photo-oxidative stress. Hum Gene Ther. 2004;15(10):960-967.
23. Liu Y, Tang L, Chen B. Effects of antioxidant gene therapy on retinal neurons and oxidative stress in a model of retinal ischemia/reperfusion. Free Radic Biol Med. 2012;52(5):909-915.
24. Kanninen K, et al. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106(38):16505-16510.
25. Nanou A, et al. Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis. Mol Ther. 2013;21(8):1486-1496.
26. Fahim AT, Daiger SP, Weleber RG. Retinitis pigmentosa overview. In: Pagon RA, et al., eds. GeneReviews. Seattle, Washington, USA: University of Washington; 2000.
27. Ran X, et al. "RetinoGenetics": a comprehensive mutation database for genes related to inherited retinal degeneration. Database (Oxford). 2014;2014:bau047.
28. Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa. Clin Genet. 2013;84(2):132-141.
29. Shen J, et al. Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J Cell Physiol. 2005;203(3):457-464.
30. Komeima K, Rogers BS, Lu L, Campochiaro PA. Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A. 2006;103(30):11300-11305.
31. Usui S, et al. Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. Mol Ther. 2009;17(5):778-786.
32. Anderson D. The optic nerve in glaucoma. In: Tasman W, Jaeger EA, eds. Duane's Ophthalmology. Vol.3 Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins; 2013:Chapter48.
33. Kanamori A, Catrinescu MM, Kanamori N, Mears KA, Beaubien R, Levin LA. Superoxide is an associated signal for apoptosis in axonal injury. Brain. 2010;133(9):2612-2625.
34. Lieven CJ, Hoegger MJ, Schlieve CR, Levin LA. Retinal ganglion cell axotomy induces an increase in intracellular superoxide anion. Invest Ophthalmol Vis Sci. 2006;47(4):1477-1485.
35. Taoka Y, Naruo M, Koyanagi E, Urakado M, Inoue M. Superoxide radicals play important roles in the pathogenesis of spinal cord injury. Parapleigia. 1995;33(8):450-453.
36. Kurimoto T, et al. Long-distance axon regeneration in the mature optic nerve: contributions of oncomodulin, cAMP, and pten gene deletion. J Neurosci. 2010;30(46):15654-15663.
37. de Lima S, et al. Full-length axon regeneration in the adult mouse optic nerve and partial recovery of simple visual behaviors. Proc Natl Acad Sci U S A. 2012;109(23):9149-9154.
38. Yin Y, et al. Oncomodulin is a macrophagederived signal for axon regeneration in retinal ganglion cells. Nat Neurosci. 2006;9(6):843-852.
39. Park KK, et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science. 2008;322(5903):963-966.
40. Hoang QV, Linsenmeier RA, Chung CK, Curcio CA. Photoreceptor inner segments in monkey and human retina: mitochondrial density, optics, and regional variation. Vis Neurosci. 2002;19(4):395-407.
41. Nohl H, Hegner D. Do mitochondria produce oxygen radicals in vivo? Eur J Biochem. 1978;82(2):563-567.
42. Wellard J, Lee D, Valter K, Stone J. Photoreceptors in the rat retina are specifically vulnerable to both hypoxia and hyperoxia. Vis Neurosci. 2005;22(4):501-507.
43. Yu D, Cringle SJ, Su E, Yu PK. Intraretinal oxygen levels before and after photoreceptor loss in the RCS rat. Invest Ophthalmol Vis Sci. 2000;41(12):3999-4006.
44. Yu DY, Cringle SJ. Retinal degeneration and local oxygen metabolism. Exp Eye Res. 2005;80(6):745-751.
45. Watanabe S, Sanuki R, Ueno S, Koyasu T, Hasegawa T, Furukawa T. Tropisms of AAV for subretinal delivery to the neonatal mouse retina and its application for in vivo rescue of developmental photoreceptor disorders. PLoS One. 2013;8(1):e54146.
46. Natkunarajah M, et al. Assessment of ocular transduction using single-stranded and selfcomplementary recombinant adeno-associated virus serotype 2/8. Gene Ther. 2008;15(6):463-467.
47. Chang B, et al. Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene. Vision Res. 2007;47(5):624-633.
48. Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci. 2009;12(1):44-52.
49. Lee JM, Shih AY, Murphy TH, Johnson JA. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem. 2003;278(39):37948-37956.
50. Gargini C, Terzibasi E, Mazzoni F, Strettoi E. Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: a morphological and ERG study. J Comp Neurol. 2007;500(2):222-238.
51. Lem J, et al. Morphological, physiological, and biochemical changes in rhodopsin knockout mice. Proc Natl Acad Sci U S A. 1999;96(2):736-741.
52. Rohrer B, Lohr HR, Humphries P, Redmond TM, Seeliger MW, Crouch RK. Cone opsin mislocalization in Rpe65-/-mice: a defect that can be corrected by 11-cis retinal. Invest Ophthalmol Vis Sci. 2005;46(10):3876-3882.
53. Prusky GT, Alam NM, Beekman S, Douglas RM. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci. 2004;45(12):4611-4616.
54. De Lima S, Habboub G, Benowitz LI. Combinatorial therapy stimulates long-distance regeneration, target reinnervation, and partial recovery of vision after optic nerve injury in mice. Int Rev Neurobiol. 2012;106:153-172.
55. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the f-globin locus control region. Proc Natl Acad Sci U S A. 1994;91(21):9926-9930.
56. Lee SY, et al. N-acetylcysteine promotes longterm survival of cones in a model of retinitis pigmentosa. J Cell Physiol. 2011;226(7):1843-1849.
57. Hauswirth WW, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19(10):979-990.
58. Bainbridge JW, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2231-2239.
59. Maguire AM, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2240-2248.
60. Clark J, Simon DK. Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal. 2009;11(3):509-528.
61. Malhotra D, et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 2010;38(17):5718-5734.
62. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 2002;62(18):5196-5203.
63. Reisman SA, Yeager RL, Yamamoto M, Klaassen CD. Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. Toxicol Sci. 2009;108(1):35-47.
64. Fox RJ, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097.
65. Gold R, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.
66. Saint-Geniez M, et al. PGC-1a regulates normal and pathological angiogenesis in the retina. Am J Pathol. 2013;182(1):255-265.
67. Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL. Sustained expression of PGC-1a in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet. 2012;21(8):1861-1876.
68. Izzott A, Bagnis A, Sacca S. The role of oxidative stress in glaucoma. Mutat Res. 2006; 612(2):105-114.
69. Beatty S, Koh H, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of agerelated macular degeneration. Surv Ophthalmol. 2000;45(2):115-134.
70. Justilien V, et al. SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci. 2007;48(10):4407-4420.
71. Girmens JF, Sahel JA, Marazova K. Dry age-related macular degeneration: a currently unmet clinical need. Intractable Rare Dis Res. 2012;1(3):103-114.
72. Streichert LC, Birnbach CD, Reh TA. A diffusible factor from normal retinal cells promotes rod photoreceptor survival in an in vitro model of retinitis pigmentosa. J Neurobiol. 1999;39(4):475-490.
73. Mohand-Said S, Hicks D, Dreyfus H, Sahel JA. Selective transplantation of rods delays cone loss in a retinitis pigmentosa model. Arch Ophthalmol. 2000;118(6):807-811.
74. Leveillard T, et al. Identification and characterization of rod-derived cone viability factor. Nat Genet. 2004;36(7):755-759.
75. Steinberg RH. Survival factors in retinal degenerations. Curr Opin Neurobiol. 1994;4(4):515-524.
76. Mohand-Said S, et al. Normal retina releases a diffusible factor stimulating cone survival in the retinal degeneration mouse. Proc Natl Acad Sci U S A. 1998;95(14):8357-8362.
77. Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp Eye Res. 2003;76(4):463-471.
78. Cepko CL. Emerging gene therapies for retinal degenerations. J Neurosci. 2012;32(19):6415-6420.
79. Busskamp V, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science. 2010;329(5990):413-417.
80. Himori N, et al. Critical role of Nrf2 in oxidative stress-induced retinal ganglion cell death. J Neurochem. 2013;127(5):669-680.
81. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A. 1996;93(7):2696-2701.
82. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 1996;737(1):195-200.
83. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem. 1998;70(1):268-275.
84. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1989;1(8649):1269.
85. Chomyn A, Attardi G. MtDNA mutations in aging and apoptosis. Biochem Biophys Res Commun. 2003;304(3):519-529.
86. Bender A, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006;38(5):515-517.
87. Matigian N, et al. Disease-specific, neurosphere-derived cells as models for brain disorders. Dis Model Mech. 2010;3(11-12):785-798.
88. Ramsey CP, et al. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol. 2007;66(1):75-85.
89. Kaidery NA, et al. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal. 2013;18(2):139-157.
90. Gan L, Vargas MR, Johnson DA, Johnson JA. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J Neurosci. 2012;32(49):17775-17787.
91. Solis LM, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010;16(14):3743-3753.
92. Zhang P, et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther. 2010;9(2):336-346.
93. Ryan D, King A, Thomas G. Cleavage of footand-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol. 1991;72(11):2727-2732.
94. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc. 2006;1(3):1412-1428.
95. Vandenberghe LH, Xiao R, Lock M, Lin J, Korn M, Wilson JM. Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther. 2010;21(10):1251-1257.
96. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci U S A. 2004;101(1):16-22.
97. Wang S, Sengel C, Emerson M, Cepko C. The binary decision of rod and bipolar fate in the vertebrate retina is controlled by a gene regulatory network. Dev Cell. 2014;30(5):513-527.
98. Douglas RM, Alam NM, Silver BD, McGill TJ, Tschetter WW, Prusky GT. Independent visual threshold measurements in the two eyes of freely moving rats and mice using a virtual-reality optokinetic system. Vis Neurosci. 2005;22(5):677-684.